Achieve Life Sciences Appoints Two New Directors to Key Board Committees
ACHV has more than doubled off its 52-week low of $2.
Summary
Achieve Life Sciences appointed Jeff Farrow and Reid Waldman, M.D. as new independent directors, with Farrow chairing the Audit Committee and Waldman chairing the Compensation Committee.
Key Events · Executive and Board Changes · ACHV
-
New Director Appointments
Jeff Farrow and Reid Waldman, M.D. were appointed to the Board of Directors, effective May 29, 2026.
-
Key Committee Leadership
Jeff Farrow will chair the Audit Committee and serve on the Nominating and Governance Committee. Dr. Reid Waldman will chair the Compensation Committee and serve on the Commercial Committee.
-
Director Compensation
Each new director will receive a pro-rated $40,000 annual retainer, additional cash for committee service, and stock options to purchase 47,250 shares of common stock vesting over three years.
Analysis · ACHV · Life Sciences
The appointment of two new independent directors, one chairing the Audit Committee and the other the Compensation Committee, is a significant step in strengthening corporate governance. This follows a period of substantial capital raises, a 'going concern' warning, and prior board and CEO changes, indicating a strategic move to enhance oversight and stability during a critical phase for the company.
At the time of this filing, ACHV was trading at $5.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $544.1M. The 52-week trading range was $2.00 to $6.15. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.